Literature DB >> 19088933

Use of activated protein C has no avail in the early phase of acute pancreatitis.

Sinan Akay1, Omer Ozutemiz, Cigdem Yenisey, Nilufer Genc Simsek, Gul Yuce, Yucel Batur.   

Abstract

OBJECTIVES: Sepsis and acute pancreatitis have similar pathogenetic mechanisms that have been implicated in the progression of multiple organ failure. Drotrecogin alfa, an analogue of endogenous protein C, reduces mortality in clinical sepsis. Our objective was to evaluate the early therapeutic effects of activated protein C (APC) in a rat model of acute necrotizing pancreatitis. SUBJECTS AND
METHOD: Acute necrotizing pancreatitis was induced by intraductal injection of 5% Na taurocholate. Hourly bolus injections of saline or recombinant human APC (drotrecogin alfa) was commenced via femoral venous catheter four hours after the induction of acute pancreatitis. The experiment was terminated nine hours after pancreatitis induction. Animals in group one (n=20) had a sham operation while animals in group two (n=20) received saline and animals in group three (n=20) received drotrecogin alfa boluses after acute pancreatitis induction. Pancreatic tissue for histopathologic scores and myeloperoxidase, glutathione reductase, glutathione peroxidase, and catalase activities were collected, and blood for serum amylase, urea, creatinine, and interleukin-6 measurements was withdrawn.
RESULTS: Serum amylase activity was significantly lower in the APC treated group than the untreated group (17,435+/-432 U/L vs. 27,426+/-118 U/L, respectively). While the serum interleukin-6 concentration in the APC untreated group was significantly lower than the treated group (970+/-323 pg/mL vs. 330+/-368 pg/mL, respectively).
CONCLUSION: In the early phase of acute pancreatitis, drotrecogin alfa treatment did not result in a significant improvement in oxidative and inflammatory parameters or renal functions.

Entities:  

Keywords:  activated protein C; acute pancreatitis; catalase; drotrecogin alfa; glutathione peroxidase; glutathione reductase; myeloperoxidase; oxidative stress

Year:  2008        PMID: 19088933      PMCID: PMC2597320          DOI: 10.1080/13651820802140729

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  24 in total

1.  Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties.

Authors:  M A Matthay
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Frequency and time course of pancreatic and extrapancreatic bacterial infection in experimental acute pancreatitis in rats.

Authors:  M Schwarz; J Thomsen; H Meyer; M W Büchler; H G Beger
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

3.  Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit.

Authors:  L H Ottesen; E M Bladbjerg; M Osman; S B Lausten; N O Jacobsen; J Gram; S L Jensen
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

4.  Heterogeneity of erythrocyte catalase II. Isolation and characterization of normal and variant erythrocyte catalase and their subunits.

Authors:  H Aebi; S R Wyss; B Scherz; F Skvaril
Journal:  Eur J Biochem       Date:  1974-10-01

5.  Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.

Authors:  D E Paglia; W N Valentine
Journal:  J Lab Clin Med       Date:  1967-07

Review 6.  Acute pancreatitis as a model of sepsis.

Authors:  P G Wilson; M Manji; J P Neoptolemos
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

7.  Effect of fludarabine on leukocyte functions.

Authors:  A Lale Doğan; Ayça Doğan; Hande Canpinar; Ovunç Duzgunçinar; Ediz Demirpençe
Journal:  Chemotherapy       Date:  2004-12-08       Impact factor: 2.544

Review 8.  Interaction between cytokines and oxidative stress in acute pancreatitis.

Authors:  Javier Pereda; Luis Sabater; Luis Aparisi; Javier Escobar; Juan Sandoval; José Viña; Gerardo López-Rodas; Juan Sastre
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

9.  Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis.

Authors:  Dejan Radenković; Djordje Bajec; Aleksandar Karamarkovic; Branislav Stefanovic; Natasa Milic; Svetlana Ignjatović; Pavle Gregoric; Miroslav Milicevic
Journal:  Pancreas       Date:  2004-08       Impact factor: 3.327

10.  Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases.

Authors:  Ping Chen; Yongping Zhang; Minmin Qiao; Yaozong Yuan
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

View more
  3 in total

1.  Activated protein C improves the severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin.

Authors:  Chen Ping; Zhang Yongping; Qiao Minmin; Yao Weiyan; Yuan Yaozong
Journal:  Dig Dis Sci       Date:  2009-08-13       Impact factor: 3.199

2.  APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.

Authors:  Ville Pettilä; Lea Kyhälä; Marja-Leena Kylänpää; Ari Leppäniemi; Minna Tallgren; Antti Markkola; Pauli Puolakkainen; Heikki Repo; Esko Kemppainen
Journal:  Crit Care       Date:  2010-07-27       Impact factor: 9.097

Review 3.  The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications.

Authors:  Paulina Dumnicka; Dawid Maduzia; Piotr Ceranowicz; Rafał Olszanecki; Ryszard Drożdż; Beata Kuśnierz-Cabala
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.